Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 191

1.

DEXAMETHASONE STRESS TEST: A PILOT CLINICAL STUDY FOR IDENTIFICATION OF INDIVIDUALS HIGHLY PRONE TO DEVELOP TYPE 2 DIABETES.

Taheri N, Aminorroaya A, Ismail-Beigi F, Amini M.

Endocr Pract. 2018 Aug 7. doi: 10.4158/EP-2018-0188. [Epub ahead of print]

PMID:
30084689
2.

Relationships between cerebral structure and cognitive function in African Americans with type 2 diabetes.

Hughes TM, Sink KM, Williamson JD, Hugenschmidt CE, Wagner BC, Whitlow CT, Xu J, Smith SC, Launer LJ, Barzilay JI, Ismail-Beigi F, Bryan RN, Hsu FC, Bowden DW, Maldjian JA, Divers J, Freedman BI; AA-DHS MIND and ACCORD MIND Investigators.

J Diabetes Complications. 2018 Oct;32(10):916-921. doi: 10.1016/j.jdiacomp.2018.05.017. Epub 2018 May 29.

PMID:
30042057
3.

Structure-based stabilization of insulin as a therapeutic protein assembly via enhanced aromatic-aromatic interactions.

Rege NK, Wickramasinghe NP, Tustan AN, Phillips NFB, Yee VC, Ismail-Beigi F, Weiss MA.

J Biol Chem. 2018 Jul 13;293(28):10895-10910. doi: 10.1074/jbc.RA118.003650. Epub 2018 Jun 7.

PMID:
29880646
4.

An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein.

Glidden MD, Aldabbagh K, Phillips NB, Carr K, Chen YS, Whittaker J, Phillips M, Wickramasinghe NP, Rege N, Swain M, Peng Y, Yang Y, Lawrence MC, Yee VC, Ismail-Beigi F, Weiss MA.

J Biol Chem. 2018 Jan 5;293(1):47-68. doi: 10.1074/jbc.M117.808626. Epub 2017 Nov 7.

PMID:
29114035
5.

Solution structure of an ultra-stable single-chain insulin analog connects protein dynamics to a novel mechanism of receptor binding.

Glidden MD, Yang Y, Smith NA, Phillips NB, Carr K, Wickramasinghe NP, Ismail-Beigi F, Lawrence MC, Smith BJ, Weiss MA.

J Biol Chem. 2018 Jan 5;293(1):69-88. doi: 10.1074/jbc.M117.808667. Epub 2017 Nov 7.

PMID:
29114034
6.

Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016).

Esteghamati A, Larijani B, Aghajani MH, Ghaemi F, Kermanchi J, Shahrami A, Saadat M, Esfahani EN, Ganji M, Noshad S, Khajeh E, Ghajar A, Heidari B, Afarideh M, Mechanick JI, Ismail-Beigi F.

Sci Rep. 2017 Oct 18;7(1):13461. doi: 10.1038/s41598-017-13379-z.

7.

The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident CVD in People With Diabetes: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study.

Cukierman-Yaffe T, Gerstein HC, Miller ME, Launer LJ, Williamson JD, Horowitz KR, Ismail-Beigi F, Lazar RM.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3218-3225. doi: 10.1210/jc.2016-3480.

8.

Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials.

Ismail-Beigi F, Moghissi E, Kosiborod M, Inzucchi SE.

J Gen Intern Med. 2017 Sep;32(9):1044-1051. doi: 10.1007/s11606-017-4061-7. Epub 2017 May 26. Review.

9.

Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes.

Hashemi Madani N, Ismail-Beigi F, Khamseh ME, Malek M, Ebrahimi Valojerdi A.

Eur J Prev Cardiol. 2017 Jul;24(11):1181-1189. doi: 10.1177/2047487317707293. Epub 2017 Apr 27.

PMID:
28447480
10.

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2017 Apr;40(4):e47-e48. doi: 10.2337/dci16-0048. No abstract available.

11.

Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.

Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP; ACCORDION Study Investigators.

JAMA Cardiol. 2017 Apr 1;2(4):370-380. doi: 10.1001/jamacardio.2016.4828.

12.

Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.

Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN; IRIS Trial Investigators.

Diabetes Care. 2016 Oct;39(10):1684-92. doi: 10.2337/dc16-0798. Epub 2016 Jul 27.

13.

Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial.

Nadkarni GN, Rao V, Ismail-Beigi F, Fonseca VA, Shah SV, Simonson MS, Cantley L, Devarajan P, Parikh CR, Coca SG.

Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1343-52. doi: 10.2215/CJN.12051115. Epub 2016 May 17.

14.

Insulin Dose and Cardiovascular Mortality in the ACCORD Trial.

Siraj ES, Rubin DJ, Riddle MC, Miller ME, Hsu FC, Ismail-Beigi F, Chen SH, Ambrosius WT, Thomas A, Bestermann W, Buse JB, Genuth S, Joyce C, Kovacs CS, O'Connor PJ, Sigal RJ, Solomon S; ACCORD Investigators.

Diabetes Care. 2015 Nov;38(11):2000-8. doi: 10.2337/dc15-0598. Epub 2015 Oct 13.

15.

Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.

Zonszein J, Lombardero M, Ismail-Beigi F, Palumbo P, Foucher S, Groenewoud Y, Cushing G, Wajchenberg B, Genuth S; Bari 2D Study Group.

J Diabetes Res. 2015;2015:129891. doi: 10.1155/2015/129891. Epub 2015 May 27.

16.

Aromatic anchor at an invariant hormone-receptor interface: function of insulin residue B24 with application to protein design.

Pandyarajan V, Smith BJ, Phillips NB, Whittaker L, Cox GP, Wickramasinghe N, Menting JG, Wan ZL, Whittaker J, Ismail-Beigi F, Lawrence MC, Weiss MA.

J Biol Chem. 2014 Dec 12;289(50):34709-27. doi: 10.1074/jbc.M114.608562. Epub 2014 Oct 10.

17.

Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial.

Zhang Z, Lovato J, Battapady H, Davatzikos C, Gerstein HC, Ismail-Beigi F, Launer LJ, Murray A, Punthakee Z, Tirado AA, Williamson J, Bryan RN, Miller ME.

Diabetes Care. 2014 Dec;37(12):3279-85. doi: 10.2337/dc14-0973. Epub 2014 Sep 29.

18.

The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.

Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT; Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group.

Ophthalmology. 2014 Dec;121(12):2443-51. doi: 10.1016/j.ophtha.2014.07.019. Epub 2014 Aug 29.

19.

The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial.

Mottl AK, Pajewski N, Fonseca V, Ismail-Beigi F, Chew E, Ambrosius WT, Greven C, Schubart U, Buse J.

J Diabetes Complications. 2014 Nov-Dec;28(6):874-9. doi: 10.1016/j.jdiacomp.2014.07.001. Epub 2014 Jul 12.

20.

Risk of insulin accumulation (stacking) with use of novel ultralong-acting insulin formulations.

Bansal V, Davis GM, Ismail-Beigi F.

Endocr Pract. 2014 Sep;20(9):990-1. doi: 10.4158/EP14144.CO. No abstract available.

PMID:
25100381

Supplemental Content

Loading ...
Support Center